Immunovant to Present at Roivant Investor Day on September 28th
NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal...
Pharmaceutical
Blue Water Vaccines to Present at World Vaccine Congress Europe 2022
CINCINNATI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a...
Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase III Trial for Relapsing forms of Multiple Sclerosis (RMS)
The study evaluating a long-acting glatiramer acetate injection, GA Depot 40 mg once every four weeks, met the primary endpoint,...
Acerus Announces Initiation of Strategic Review
Ernst & Young Orenda Corporate Finance Inc. (“EY”) engaged as independent financial advisorsTORONTO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Acerus...
Lexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic Neuropathy
Poster and Oral Presentation at PAINWeek Describing a Novel Mechanism of Action for Neuropathic Pain Poster at International Association for...
DynamiCure Announces Appointment of Industry Veteran Peter Lasky as its First Chief People Officer
Appointment strengthens senior leadership team as company advances its first candidate into the clinic and prepares to expand its pipeline...
Centessa Pharmaceuticals Announces Poster Presentation Featuring Novel Orexin Receptor 2 (OX2R) Agonist Discovery Pipeline at the 26th Conference of the European Sleep Research Society (Sleep Europe 2022)
– Data demonstrate potent efficacy of small-molecule OX2R agonists in a non-clinical model of narcolepsy type 1 (NT1) –– Company...
Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial
STS101 demonstrated a favorable safety and tolerability profile, consistent with clinical experience to dateOver 8,000 migraine attacks treated with more...
Merck Joins Accumulus Synergy as a Sponsor to Transform the Global Drug Regulatory Submission Process
A dozen global pharmaceutical companies have joined effort to accelerate critical therapies to citizens of the worldBURLINGAME, Calif., Sept. 20,...
Evoke Pharma Receives Notice of Allowance from USPTO for a Patent Related to GIMOTI
SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily...
Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing
First use of Ciitizen platform as source of real-world data in regulatory filingSAN FRANCISCO and BOSTON, Sept. 20, 2022 (GLOBE...
CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development
Advanced insights from CytoReason’s disease models will support Pfizer’s drug development processTEL AVIV, Israel, Sept. 20, 2022 (GLOBE NEWSWIRE) --...
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Ireland
Reimbursement granted with no restrictions to the labelATLANTA, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”),...
Applied Molecular Transport Completes Enrollment of Phase 2 LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
Top-line data readout anticipated late 2022 or early 2023SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Applied Molecular...
Orchestra BioMed™ Announces Presentation of Positive Long-Term Clinical Results from MODERATO II Control Patients Crossover Extension Study of BackBeat CNT™ at TCT 2022
Statistically significant mean reductions of 10.3 mmHg in 24-hour ambulatory systolic blood pressure and 11.7 mmHg in ambulatory pulse pressure...
Humacyte Expands Board of Directors and Leadership Team with New Appointments
Lt. General Bruce Green, M.D., USAF-ret. Joins Board of Directors Cindy Cao, Ph.D. Appointed as Chief Regulatory Officer DURHAM, N.C.,...
Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of Directors
Mr. Novak brings over 30 years of board and management experience at innovative life sciences companiesMIAMI BEACH, Fla., Sept. 20,...
Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting Treatment for Type 2 Diabetes
Menin, a transcriptional scaffold protein, regulates pancreatic beta cell homeostasis; inhibiting menin function with BMF-219 increased beta cell function in...
Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer
Outgoing CEO Eric Richman will continue to serve as a member of the board of directors and serve as a...
BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
- The first and only treatment in Europe to treat patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare,...